Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
J. Clin. Invest. Ricardo T. Paniagua, et al. 116:2633
doi:10.1172/JCI28546 [Go to this article.]

Problems with a PDF?